Body composition after kidney transplantation is linked to glucose metabolism, and impaired glucose metabolism is associated with increased risk of cardiovascular events and death. One year after transplantation, we examined 150 patients for post-transplant diabetes performing oral glucose tolerance tests and body composition measurements including visceral adipose tissue (VAT) content from dual-energy X-ray absorptiometry scans. We found that glucose metabolism was generally improved over the first year post-transplant, and that the levels of VAT and percentage VAT of total body fat mass (VAT %totBFM ) were lowest in those with normal glucose tolerance and highest in those 
Visceral adipose tissue (VAT) is considered a marker of whole-body dysfunctional adipose tissue 15 and is associated with insulin resistance independently of body mass index (BMI). 16, 17 VAT may be an interesting link between metabolic and cardiovascular disease. Until recently, VAT has been examined in patients by computed tomography (CT) scans, but with high radiation, low availability, and significant costs, CT is obviously not suitable for screening of patients in a clinical setting. However, assessment of VAT has lately become feasible using novel validated software applied on standard dual-energy X-ray absorptiometry (DXA) scans.
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We have previously presented a cross-sectional study on patients in a stable phase 8-10 weeks after kidney transplantation, showing a close association between visceral fat and glucose metabolism.
Abdominal obesity and VAT were more strongly associated with impaired fasting glucose (IFG), IGT, and PTDM than BMI and total body fat. 7 The aim of this study was to assess the evolution of PTDM during the first year after kidney transplantation, and we also hypothesized that there would still be a close association between abnormalities in glucose metabolism and VAT measurements, as we found at 8-10 weeks after transplantation. The evolution in body composition and VAT during the first year post-transplant is not a topic in this study.
In addition, we wanted to assess the associations between glucose metabolism and estimates of insulin resistance and beta cell function.
| PATIENTS AND METHODS

| Study design and population
The study was a 1-year follow-up study of patients who received a kidney allograft at our transplant center from mid-November 2012 to the end of 2013. All patients without known diabetes were screened by an oral glucose tolerance test (OGTT) before entering the waiting list for transplantation. Figure 1 shows the patient disposition; out of 306 transplanted adult patients in the study period, 150 nondiabetic patients had a comprehensive investigation performed both 8 (to 10) weeks that was repeated 1 year after transplantation. The reason that the first time point is set to 8-10 weeks is that our center changed the time of standard care follow-up from 10 weeks post-transplant as standard to 8 weeks post-transplant for those transplanted after 19.11.12 . This was due to practical reasons and lower incidence of rejections. Further in this paper this time point will be referred to as 8 weeks post-transplant. This investigation included OGTT, DXA scans, and measurement of fasting plasma insulin. The study was approved by the Regional Ethics Committee of southeast Norway, and the study was performed according to the Helsinki Declaration, 19 and clinical and research activities are consistent with the Principles of the Declaration on Istanbul. 20 All patients signed a written informed consent. Demographics and transplant-related data for the patient cohort are shown in Table 1 . This study presents cross-sectional data for the cohort 1 year post-transplant.
| Glucose tolerance tests and HOMA indices
All the examinations were performed in the morning after an overnight fast. A standard OGTT was performed with blood sampling before and 2 hours after oral ingestion of 75 g glucose. Glucose metabolism classification was according to the ADA criteria for plasma glucose: ) − 3.5). 23, 24 Creatinine was analyzed with an enzymatic method on Modular P (Roche Diagnostics, Pleasanton, CA, USA). All patients were routinely recommended to start or continue on statin treatment after 3 months post-transplant.
| Body composition
Total body composition was determined by DXA using a narrow fan- Living donor, n (%) 43 (29) 25 (31) 12 (32) 4 (24) 2 (14) .576
a Acute rejection, n (%) 22 (15) 8 (10) 8 (21) 5 (29) 1 (7) . Jonckheere-Terpstra test for ordered alternatives. c GFR was measured based on clearance of a filtration marker and is given in mL/min/1.73 m (Figure 1 ), five eligible patients used cyclosporine. These few patients were excluded as the diabetogenic effect may differ between cyclosporine and tacrolimus, 26, 27 and we wanted to obtain a most homogenous cohort. Table 1 Table 2 shows the body composition and glucose metabolism indices for the patients with NGT, IFG, IGT, and PTDM at 1 year posttransplant. BMI, total body mass, total body fat mass, and VAT measures were significantly different among the different groups of glucose tolerance, and the glucose measurements expressed differences between groups as expected. Plasma insulin values and HOMA-IR index were higher with worsening glucose tolerance category, while HOMA-beta was lowest in those with PTDM. 
| Statistical analyses
| RESULTS
| Glucose metabolism improved during the first year after transplantation
| Total fat and visceral fat differ between glucose tolerance groups at 1 year after transplantation
| Linear regression analyses
| DISCUSSION
In the present study, we found a general improvement in glucose metabolism during the first year after transplantation and the incidence of PTDM was reduced from 13% to 9%. This reversibility of PTDM is in line with findings in previous studies. 28, 29 VAT measures were strongly associated with hyperglycemia and PTDM at 1 year, also in line with previous findings in kidney transplant patients early after transplantation. . is a known determinant for obesity and weight gain after transplantation, 37 stimulating a more abdominal distribution of fat. 38 Patients with PTDM did not have a higher median daily dosage of prednisolone than the rest of the patients, but they had a higher trough value of tacrolimus that is known to be diabetogenic.
T A B L E 2 Comparison of body composition and glucose metabolism between patients in different glucose tolerance categories at 1 year post-transplant
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T A B L E 3 Univariable and multivariable linear regression of determinants of fasting plasma glucose concentration at 1 year post-transplant This limits the assessability of BMI as a covariate, but on the other hand, it reflects the true clinical situation. Anyhow, using BMI >30 kg/ m 2 as the definition of obesity also implicates that individuals with a high amount of lean mass (muscle) and low fat mass will be categorized as obese. This is not favorable when it is the distribution of fat and especially abdominal obesity that is the key correlate to the adverse effects of obesity and not BMI.
41
VAT seems to be representative of whole-body adipose tissue dysfunction. As such, accumulation of VAT is a consequence of limited storage of fat in peripheral subcutaneous adipose tissue, and this limited storage results in energy overflow, lipotoxicity, and fatty infiltration in nonadipose tissue including visceral accumulation.
15
Decreasing VAT selectively through omentectomy has failed to improve glucose metabolism in obese patients. 42 It is therefore probably more important to reduce whole-body fat dysfunction than VAT by itself. 17 Obesity leads to a dysregulated secretion of adipokines with essential roles including regulation of appetite and satiety, distribution of fat, insulin sensitivity, and insulin secretion. Prophylaxis and treatment of obesity are probably by far the best approach including stimulation to physical activity and reduced caloric intake. The importance of lifestyle measures for improvement of outcomes in kidney transplant patients is a topic of increasing interest. There is some evidence that active lifestyle modifications in these patients could improve glucose metabolism, 43 and a randomized controlled study assessing nutrition intervention and exercise has recently been launched. 44 In our clinic, all patients were offered free admittance to training facilities and generally exercise at least three times weekly during the first 8 weeks after transplantation, and they are encouraged to continue an active lifestyle after discharge from the hospital.
The findings in our study pinpoint the role of VAT in posttransplant hyperglycemia and PTDM. The study demonstrates that VAT measurements are feasible in larger cohorts of patients and allow for future clinical studies on the mechanisms and hopefully treatment options of modifiable factors associated with PTDM. It should also be kept in mind that BMI and VAT changes over time are not necessarily mirrored.
Our study has some limitations. It was restricted to Caucasians, and the results may not apply to other ethnical groups. The number of patients in each glucose tolerance group was limited. We performed OGTT only once, and not twice which is preferable to establish the diagnosis of diabetes. 21 Furthermore, the present study is observational, and we have only demonstrated associations and not causality.
In conclusion, we have demonstrated an improvement of glucose metabolism 1 year after transplantation and that VAT measurements are strongly associated with hyperglycemia 1 year after kidney T A B L E 4 Univariable and multivariable linear regression of determinants of 2-hour plasma glucose concentration after an OGTT at 1 year post-transplant Unstandardized coefficients refer to how many units the dependent variable changes per unit change in an independent variable. Standardized coefficients refer to how many standard deviations the dependent variable changes per standard deviation change in the independent variable, and this shows which independent variable has a greater effect on the dependent variables.
transplantation. VAT along with measures of insulin resistance and release was the most robust marker of glucose metabolism at 1 year post-transplant.
